Article info
PostScript
Letter
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis
- Correspondence to Dr Nevin John, Neuroinflammation, UCL Institute of Neurology, London WC1N 3BG, UK; nevin.john{at}ucl.ac.uk
Citation
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis
Publication history
- Received February 22, 2019
- Revised April 15, 2019
- Accepted April 16, 2019
- First published May 11, 2019.
Online issue publication
April 06, 2020
Article Versions
- Previous version (14 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.